Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Pertuzumab Compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer With HER-2 Amplification
NCT03365882Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2017
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab in colorectal cancer (CRC), sponsored by SWOG Cancer Research Network. Started Nov 2017; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03365882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365882.